Business context and reporting period
Insulet Corporation’s Form 10-K covers the fiscal year ended December 31, 2020; it does not provide standalone fourth-quarter results. The company develops and sells the Omnipod insulin-delivery system and related DASH platform. Most revenue comes from Omnipod sales; drug-delivery revenue largely reflects pods supplied for Amgen’s Neulasta Onpro kit.
Financial performance and liquidity
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | $904.4 million | $738.2 million |
| Gross profit / gross margin | $582.3 million / 64.4% | $480.3 million / 65.1% |
| Operating income | $51.5 million | $50.0 million |
| Net income / diluted EPS | $6.8 million / $0.10 | $11.6 million / $0.19 |
| Operating cash flow | $84.0 million | $98.4 million |
- Revenue rose 22.5% reported and 21.9% at constant currency. Omnipod revenue increased 24.0% to $834.9 million; drug-delivery revenue increased 7.4% to $69.5 million.
- U.S. Omnipod revenue grew 25.3% to $526.9 million; international Omnipod revenue grew 21.7% to $308.0 million. Approximately 34% of revenue was denominated in foreign currencies.
- Gross margin declined 70 basis points, mainly due to startup costs and inefficiencies on the added U.S. manufacturing line, underused capacity and COVID-related costs.
- Research and development expense increased 11.0% to $146.8 million; selling, general and administrative expense rose 28.9% to $384.0 million. Net interest expense increased to $45.1 million from $27.7 million.
- Cash and cash equivalents were $907.2 million, with $40.4 million of short-term investments. Total debt was $1.059 billion on the balance sheet, including $1.203 billion principal of convertible notes, plus equipment financing and a mortgage. Management said liquidity should cover projected operating, investing and debt-service needs for at least 12 months.
- Capital expenditures were $129.0 million. Financing cash flow of $605.5 million included $477.5 million net proceeds from a common-stock offering; operating cash flow was reduced by a $63.4 million working-capital outflow, including higher inventory.
Changes, outlook and material matters
- Compared with 2019, revenue growth accelerated the business, but net income and operating cash flow declined. Adjusted EBITDA, a non-GAAP measure, increased to $146.1 million from $107.5 million.
- Management expected 2021 gross margin of 67%–70%, and strong Omnipod revenue growth, while noting COVID-related effects on customer starts could partly offset growth. No numerical revenue-growth guidance was provided.
- Omnipod 5, an automated insulin-delivery system, was targeted for launch in the first half of 2021. The company had completed the first phase of its pivotal trial, completed a pediatric study for ages two to six, and begun a Type 2 diabetes feasibility study. Timing and expanded indications remained subject to development and regulatory progress.
- Management expected 2021 R&D expense, SG&A expense and capital expenditures to increase, reflecting product development, commercial expansion and manufacturing capacity investment. The company began producing on a second U.S. manufacturing line in 2020 and expected sellable production from a third line in 2021.
- COVID-19 disrupted new customer starts and posed risks to demand, clinical-trial timelines and supply continuity. Other key risks include dependence on Omnipod, reimbursement and customer retention, competition, concentrated manufacturing and sole-source components, cybersecurity, foreign exchange and regulatory compliance.
- Roche sued Insulet in 2020 over an expired patent and seeks monetary damages and fees; Insulet disputes the claims. The company could not estimate a potential loss, which could be material. Insulet separately brought a U.K. patent case against Roche.
- In December 2020, Insulet settled a former European distributor fee dispute with an additional $36.2 million payment, recording a customer-relationship intangible asset and $14.6 million cumulative amortization expense.
- Insulet identified an error in its previously issued nine-month 2020 cash-flow presentation. It concluded the error was not material and said it would correct the affected cash-flow line items prospectively in a later filing; net income and the change in cash were unaffected.
- The auditor issued unqualified opinions on the financial statements and internal control over financial reporting; management and the auditor reported effective internal controls as of year-end.
Important facts for investors to verify
- Whether Omnipod 5 launch, regulatory milestones and planned indication expansions occurred on the expected timelines.
- Whether the projected gross-margin improvement and revenue growth materialized, especially given COVID-related customer-start effects and manufacturing ramp costs.
- Cash generation, inventory growth, planned capital spending and the company’s ability to service or refinance its debt; assess potential dilution from convertible notes.
- Updates on the Roche litigation, including any estimate or recognition of potential losses.
- The final correction and presentation of the nine-month 2020 cash-flow figures in subsequent filings.
- Exposure to major channels and customers: Anda and Cardinal each represented at least 10% of 2020 revenue; approximately 70% of Omnipod sales used intermediaries.